Figure 7.

Patient-Derived iNSC Therapy for Diffuse Primary GBM

GBM8-mCherry-Fluc (mCFL) were implanted into the frontal lobe of mice and partially resected 3 days later. iNSC-7-Ts were implanted on GEM scaffolds into the resulting resection cavity at the time of surgery (A). Representative BLI (B) and summary data (C) demonstrated inhibition of GBM progression by iNSC-Ts compared to control-treated mice (n = 10). ∗∗p < 0.01 by one-way ANOVA. (D) Kaplan-Meier survival curves demonstrating the extension in survival in mice treated with iNSC-7-Ts compared to control. (E) Representative whole-brain and high-magnification images showing GBM8 by mCherry fluorescence, 21 days after delivering iNSC-GFPs or iNSC-7-Ts into the resection cavity. ∗p < 0.05 by log-rank test.